The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
Prevention and reversal of cardiac hypertrophy by soluble epoxide hydrolase inhibitors
Open accessAbstract
Sustained cardiac hypertrophy represents one of the most common causes leading to cardiac failure. There is emerging evidence to implicate the involvement of NF-κB in the development of cardiac hypertrophy. However, several critical questions remain unanswered. We tested the use of soluble epoxide hydrolase (sEH) inhibitors as a means to enhance the biological activities of epoxyeicosatrienoic acids (EETs) to treat cardiac hypertrophy. sEH catalyzes the conversion of EETs to form the corresponding dihydroxyeicosatrienoic acids. Previous data have suggested that EETs may inhibit the activation of NF-κB-mediated gene transcription. We directly demonstrate the beneficial effects of several potent sEH inhibitors (sEHIs) in cardiac hypertrophy. Specifically, we show that sEHIs can prevent the development of cardiac hypertrophy using a murine model of pressure-induced cardiac hypertrophy. In addition, sEHIs reverse the preestablished cardiac hypertrophy caused by chronic pressure overload. We further demonstrate that these compounds potently block the NF-κB activation in cardiac myocytes. Moreover, by using in vivo electrophysiologic recordings, our study shows a beneficial effect of the compounds in the prevention of cardiac arrhythmias that occur in association with cardiac hypertrophy. We conclude that the use of sEHIs to increase the level of the endogenous lipid epoxides such as EETs may represent a viable and completely unexplored avenue to reduce cardiac hypertrophy by blocking NF-κB activation.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
NF-κB at the crossroads of life and death
Karin, M., & Lin, A. (2002) · Nature Immunology · doi:10.1038/ni0302-221 · Cited by 2,709
Cytochrome P450 and Vascular Homeostasis
Fleming, I. (2001) · Circulation Research · doi:10.1161/hh2101.099268 · Cited by 383
Cited by
Metabolism pathways of arachidonic acids: mechanisms and potential therapeutic targets
Wang, B., Wu, L., Chen, J., Dong, L., Chen, C., Wen, Z., Hu, J., Fleming, I., & Wang, D. W. (2021) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-020-00443-w · Cited by 1,414
Soluble epoxide hydrolase as a therapeutic target for cardiovascular diseases
Imig, J. D., & Hammock, B. D. (2009) · Nature Reviews Drug Discovery · doi:10.1038/nrd2875 · Cited by 614
Self-citationImpact of Soluble Epoxide Hydrolase and Epoxyeicosanoids on Human Health
Morisseau, C., & Hammock, B. D. (2013) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev-pharmtox-011112-140244 · Cited by 537
Self-citationArachidonic acid cytochrome P450 epoxygenase pathway
Spector, A. A. (2009) · Journal of Lipid Research · doi:10.1194/jlr.r800038-jlr200 · Cited by 413
Epoxides and Soluble Epoxide Hydrolase in Cardiovascular Physiology
Imig, J. D. (2012) · Physiological Reviews · doi:10.1152/physrev.00021.2011 · Cited by 365
Metadata
- Authors
- Xu, D., Li, N., He, Y., Timofeyev, V., Lu, L., Tsai, H.-J., Kim, I.-H., Tuteja, D., Mateo, R. K. P., Singapuri, A., Davis, B. B., Low, R., Hammock, B. D., & Chiamvimonvat, N.
- Venue
- Proceedings of the National Academy of Sciences
- Published
- 2006-12-05
- Volume
- 103
- Issue
- 49
- Pages
- 18733-18738
- ISSN
- 0027-8424 (ISSN-L)
- 1091-6490
- OpenAlex
- W2047786869
- Cited by
- 233
- References
- 2
- FWCI
- 4.26
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Prevention and reversal of cardiac hypertrophy by soluble epoxide hydrolase inhibitors. https://app.cochat.ai/papers/10.1073/pnas.0609158103
- The paper
- Xu, D., Li, N., He, Y., Timofeyev, V., Lu, L., Tsai, H.-J., Kim, I.-H., Tuteja, D., Mateo, R. K. P., Singapuri, A., Davis, B. B., Low, R., Hammock, B. D., & Chiamvimonvat, N. (2006). Prevention and reversal of cardiac hypertrophy by soluble epoxide hydrolase inhibitors. Proceedings of the National Academy of Sciences. https://doi.org/10.1073/pnas.0609158103
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.